Related Experiment Videos
The effect of fever on antipyrine metabolism in children
Insights
Fever significantly slows down how children eliminate antipyrine (a drug) from their saliva, indicating impaired drug metabolism during illness. This affects how medications are processed in the body when a child has a fever.
Area of Science:
- Pediatric Pharmacology
- Clinical Drug Metabolism
- Biopharmaceutics
Background:
- Drug metabolism and elimination are crucial for maintaining therapeutic drug concentrations.
- Fever is a common symptom in children that can influence physiological processes.
- Understanding how fever affects drug pharmacokinetics is essential for safe and effective pediatric medication use.
Purpose of the Study:
- To investigate the impact of fever on the elimination of antipyrine from saliva in children.
- To compare antipyrine clearance and half-life in children during febrile and afebrile states.
Main Methods:
- Saliva samples were collected from six children (aged 5 months to 5 years) to measure antipyrine elimination.
- Antipyrine clearance and half-life were determined during fever and a control afebrile period.
- Statistical analysis was performed to compare pharmacokinetic parameters between the two states.
Main Results:
- Saliva antipyrine clearance was approximately 50% lower during fever (32 +/- 13 ml kg-1 h-1) compared to afebrile periods (50 +/- 22 ml kg-1 h-1).
- The mean saliva antipyrine half-life was nearly doubled during fever (15.20 +/- 5.40 h) versus normal body temperature (9.18 +/- 2.49 h).
- Fever did not significantly alter the apparent volume of distribution of antipyrine.
Conclusions:
- Drug metabolizing ability in children is impaired during fever.
- Fever significantly reduces antipyrine elimination from saliva, suggesting altered hepatic or salivary drug metabolism.
- These findings highlight the need to consider fever's impact on drug pharmacokinetics in pediatric populations.
Abstract:
1 The elimination of antipyrine from saliva was measured in six children aged 5 months to 5 years during fever and during a control period 2-4 weeks after the cessation of fever. 2 The mean (+/- s.d.) saliva antipyrine clearance during fever, 32 +/- 13 ml kg-1 h-1, was nearly 50% less than that when the children were afebrile, 50 +/- 22 ml kg-1 h-1 (P less than 0.02). The mean saliva antipyrine half-life during fever, 15.20 +/- 5.40 h, was almost twice as long as that found when body temperature was normal, 9.18 +/- 2.49 h (P less than 0.01). The apparent volume of distribution of antipyrine was not significantly affected by fever. 3 These findings indicate that drug metabolising ability in children is impaired during fever.